Suven Pharma consolidated Q2 net up 31 pc at Rs 97 cr
The company had reported a net profit of Rs 74 crore in the July-September period of the previous fiscal.
Suven Pharmaceuticals on Saturday posted a 31 per cent increase in its consolidated net profit at Rs 97 crore for the second quarter ended September 30.
The company had reported a net profit of Rs 74 crore in the July-September period of the previous fiscal.
Revenue from operations rose to Rs 301 crore for the quarter under review, as against Rs 237 crore in the year-ago period, Suven Pharmaceuticals said in a regulatory filing.
The COVID-19 pandemic continues to impact the business and research operations in India and our wholly-owned subsidiary, Suven pharma Inc USA, it noted.
"Apart from the above, the shortage or non-availability of vessels leading to delay in shipments, increase in the transportation and distribution costs and timely non availability of materials with increase in materials cost are impacting our operations and profitability," it added.
The Hyderabad-based company primarily operates in the contract development and manufacturing operations (CDMO) segment.
See Zee Business Live TV Streaming Below:
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
04:57 PM IST
Advent International to acquire significant stake in Suven Pharma from its promoters
Exclusive: Suven Pharma promoters plan to sell entire stake
M&M Financial Services, IDFC First Bank and Suven Pharma shares: Buy, sell or hold—What should investors do with these stocks?
Q4 Results 2022: Central Bank, UPL, PVR, BLS International, Suven Pharma announce March quarter results; here are key highlights